Medica Korea

What Medica Korea does

Medica Korea Co., Ltd. (주식회사 메디카코리아) is a South Korean pharmaceutical manufacturer headquartered in Seocho-gu, Seoul, with manufacturing operations at a KGMP-compliant Hyangnam factory in Hwaseong-si, Gyeonggi-do. Founded in 1976 as Dong-il Pharmaceutical and reorganized under its current name in 2000, the company produces 340+ pharmaceutical products spanning hyperlipidemia (Rosueze Tablet), diabetes (Pioglita Tablet), neuropathic pain and anticonvulsants (Prelika Capsule), antipyretic/analgesic (Lockpain Tablet), dermatology (Nimegen Soft Capsule, an isotretinoin formulation), and a film-type erectile-dysfunction treatment (Yesgra). The prescription portfolio is sold primarily to Korean hospitals and clinics through a direct-sales motion, with approximately 60 products exported to 10-13 countries under MFDS GMP and bioequivalence certification.

Beyond prescription pharmaceuticals, Medica Korea operates three consumer-facing sub-brands — Bibi-Toktok (비비톡톡) health functional foods in popping-powder format with bilberry, probiotic, vitamin C, and collagen variants; Medica Life & Health (메디카생활건강) lifestyle wellness products; and Naience (네이언스) functional cosmetics distributed via dermatology clinics — plus a CMO contract-manufacturing service for tablets, hard capsules, and Alu-Alu/PTP packaging. The company generates additional revenue from atelocollagen research reagents and from contract manufacturing for third-party pharmaceutical clients, with KGMP, ISO 14001, and ISO 45001 certifications underpinning regulatory standing.

R&D is anchored by the MK Institute of Regenerative Medicine (MIRM) established in Sejong-si in 2019, focused on regenerative medicine, aseptic/biodegradable materials, and atelocollagen manufacturing — protected by Patent No. 10-2155509 and an additional pH titration collagen patent application. The 2016 acquisition of Protox Inc. seeded a biopharmaceutical (botulinum toxin) capability now being built out through a Botox manufacturing facility. Revenue grew from KRW 36.8 billion in 2016 to KRW 100 billion in 2022, with a stated KRW 150 billion sales target for 2025 and a 2022 World Class Plus Project award for the KDS2010 non-psychotropic obesity drug clinical program.

Name

Medica Korea

Legal name

MEDICA KOREA Co., Ltd.

Website

https://medicakorea.com

Company type

Private

Founded year

1976

Operating status

Operating

Headcount range

11–50 employees

Short description

Medica Korea is a South Korean pharmaceutical manufacturer producing 340+ prescription drugs, OTCs, health functional foods (Bibi-Toktok, Medica Life & Health), functional cosmetics (Naience), and CMO contract manufacturing services for hospitals, clinics, international distributors in 10-13 countries, and direct-to-consumer health brands.

Ownership category

akta.pro rank

Product category

Pharmaceutical Manufacturing

NAICS

Pharmaceutical Preparation Manufacturing (325412), Pharmaceutical and Medicine Manufacturing (3254), Pharmaceutical and Medicine Manufacturing (32541), Drugs and Druggists' Sundries Merchant Wholesalers (424210)

SIC

Pharmaceutical Preparations (2834), Wholesale-Drugs, Proprietaries & Druggists' Sundries (5122)

akta.pro primary industry

Specialty Care Pharmaceuticals (HLAIAAAB)

akta.pro secondary industries

Dermatology & Aesthetics Pharmaceuticals (HLAIAAAK), Contract Development & Manufacturing for Generics (CDMO/CMO) (HLAIABAI), Cold, Flu, Cough & Allergy Remedies (Decongestants, Antihistamines, Cough Syrups, Lozenges) (CRADAMAD)

Keywords

• Prescription pharmaceuticals
• Health functional foods
• Contract manufacturing services
• Generic drug manufacturing
• Dermatology therapeutics

Headquarters

HQ city

Seoul

HQ country

South Korea

HQ region

Asia

Offices4 records

Markets served

GTM type

B2B

Offering type

Hardware or Manufacturing

Cost components

Supply Chain, Operations, Personnel, Technology or R&D, Marketing or Sales, Infrastructure

Revenue model

1. Prescription Pharmaceuticals: Sale of prescription drugs (전문의약품) primarily to hospitals and clinics, including specialty medicines and general medicines. This is the primary revenue stream.
2. Over-the-counter (OTC) Drugs: Sale of OTC medications including products like Lockpain tablets and health supplements
3. Health Functional Foods: Sale of health supplements under brands like Bibi-Toktok and Medica Life & Health through online channels
4. CMO Contract Manufacturing: Contract manufacturing services for pharmaceutical products with bioequivalence certification from Ministry of Food and Drug Safety, including tablets, capsules, and packaging
5. Export Sales: Export of approximately 60 pharmaceutical products manufactured under GMP standards to 10-13 countries worldwide

Go-to-market motion2 records

Distribution channels4 records

Marketing channels7 records

Core offering

Medica Korea manufactures and sells prescription pharmaceuticals (ETC), over-the-counter (OTC) drugs, health functional foods, and functional cosmetics across therapeutic areas including hyperlipidemia, diabetes, neurology, and dermatology. The company operates a KGMP-compliant manufacturing facility producing 340+ medicines and offers CMO contract manufacturing services for tablets, capsules, and packaging under bioequivalence certification from the Korean Ministry of Food and Drug Safety.

Product overview

Medica Korea is a pharmaceutical company founded in 1976 (as Dong-il Pharmaceutical), reorganized in 2000, with a portfolio spanning prescription pharmaceuticals (ETC), over-the-counter medicines (OTC), health functional foods, functional cosmetics, and contract manufacturing services. Its core pharmaceutical portfolio includes specialty treatments in therapeutic areas such as hyperlipidemia (Rosueze Tablet), diabetes (Pioglita Tablet, Dapagle franchise), neurology/analgesia (Prelika/Pregabalin, Lockpain/Loxoprofen), and dermatology (Nimegen/Isotretinoin). The company operates two sub-brands under its consumer health division: 'Bibi-Toktok' (비비톡톡), a children's health functional food brand featuring popping powder formulas in four variants (Bilberry, Probiotics, Vitamin C, Collagen), and 'Medica Life & Health' (메디카생활건강) for general lifestyle wellness products. A third sub-brand, 'Naience' (네이언스), covers functional dermatology cosmetics. The company also offers CMO (contract manufacturing) services for tablets and hard capsules under KGMP standards, and has an R&D focus on regenerative medicine and medical collagen through its Sejong-based MK Institute of Regenerative Medicine (MIRM). Total product portfolio exceeds 195 pharmaceutical products manufactured at KGMP-certified facilities, with exports to approximately 10–13 countries.

Differentiator

Problem solved

Functional benefit

Brands

• Bibi-Toktok (비비톡톡): Health functional food brand featuring popping powder texture. Products include bilberry, probiotic, vitamin C, and collagen supplements.
• Medica Life & Health (메디카생활건강)
• Naience (네이언스)

Products and services

• Rosueze Tablet A combination hyperlipidemia treatment combining ezetimibe and rosuvastatin, designed to lower cholesterol by inhibiting intestinal cholesterol absorption and hepatic cholesterol synthesis. Sold primarily to hospitals and clinics.
• Prelika Capsule An anticonvulsant medication containing pregabalin, used for the treatment of neuropathic pain and as an adjunct therapy for partial seizures. Targeted at hospital and clinic neurology practices.
• Pioglita Tablet A diabetes treatment containing pioglitazone hydrochloride, a thiazolidinedione that improves insulin sensitivity for glycemic control in type 2 diabetes. Sold to hospitals, clinics, and pharmacies.
• Lockpain Tablet An OTC antipyretic, analgesic, and anti-inflammatory medication containing loxoprofen sodium, used for the relief of pain and fever. Sold through pharmacies and online channels.
• Nimegen Soft Capsule An acne treatment containing isotretinoin, a retinoid used for severe and recalcitrant nodular acne. Available in 10mg and 20mg strengths; the 20mg formulation was the first isotretinoin 20mg product developed in Korea.
• Yesgra Film-Type Erectile Dysfunction Treatment A film-type erectile dysfunction treatment launched in 2015, representing an innovative dosage form in Medica Korea's urology product portfolio.
• Bibi-Toktok Health Functional Food Series A health functional food brand for children and families featuring popping 'TokTok powder' that dissolves in the mouth. Includes Bilberry (premium Italian bilberry), Probiotics (DuPont Danisco 7-strain blend), Vitamin C (100mg daily), and Collagen (orange/lemon flavor). Sold through online marketplaces.
• Medica Life & Health Brand A lifestyle health brand under Medica Korea providing health and wellness products for consumers seeking daily health benefits.
• Naience Functional Cosmetics Brand A functional cosmetics brand launched in 2013, offering dermatological skincare products including cleansing, UV protection, and repair lines. Distributed through dermatology clinics and hospitals.
• Atelocollagen Reagent A research reagent containing atelocollagen Type I derived from porcine skin, supplied in 10ml and 100ml solution formats for research use. Manufacturing process validated for virus safety under international standards and covered by a granted patent.
• CMO Contract Manufacturing Services Contract manufacturing organization (CMO) services for pharmaceutical companies, producing tablets (single-layer and multi-layer), hard capsules, and Alu-Alu and PTP packaging. Products certified for bioequivalence by the Korean Ministry of Food and Drug Safety, with strict KGMP-standardized quality control.

Quantifiable outcome

• Revenue increased from KRW 368 billion (2016) to KRW 895 billion (2021)
• +3 more outcomes

Named customers2 records

Segments3 records

Ideal customer profiles4 records

Technology focussed No

API detail

Has API

No

API docs

API detail

Core technology

AI maturity

App detail

Feature3 records

Partnerships

Seven partnerships are on record, tiered minor and core.

• Konyang UniversityminorStrategic or Co-development Partner · 1 June 2022Signed business agreement for building a smart factory at Konyang University in June 2022 to advance manufacturing capabilities.
• AgathonbiominorStrategic or Co-development Partner · 1 March 2022Signed exclusive supply business agreement in March 2022 to expand raw material market for medical devices.
• IncospharmminorStrategic or Co-development Partner · 1 January 2022Signed business agreement in January 2022 for pharmaceutical technology-based peptide material development.
• Ieum Animal Medical CenterminorStrategic or Co-development Partner · 1 August 2021Signed business agreement in August 2021 for medical device development and diagnosis business cooperation.
• Synergy PartnerscoreChannel Partner/ Reseller/ Distributor · 16 March 2021Synergy Partners group company Medica Korea launched the Bibi-Toktok health functional food brand series through this partnership. Bibi-Toktok includes 4 products: bilberry, probiotics, vitamin C, and collagen, sold through online marketplaces (Tmon, Wemakeprice, Coupang).
• Nanding Material (China)minorStrategic or Co-development Partner · 1 December 2019Signed business agreement in December 2019 for joint development of material medical devices in Nanding, China.
• Protox Inc.coreStrategic or Co-development Partner · 1 August 2016Medica Korea acquired Protox Inc. in August 2016, expanding into botulinum toxin products and strengthening its position in specialized pharmaceutical areas.

Scale indicators5 records

Recent moves11 records

Expansion highlights6 records

Broad incumbents

• Yuhan Corporation: One of Korea's largest pharmaceutical companies, operating across branded prescription drugs, OTC products, consumer health, and CMO. Comparable to Medica Korea in therapeutic breadth (cardiovascular, diabetes, dermatology) but at substantially greater scale and with broader export reach.
• Dong-A Pharmaceutical: Major Korean pharma with branded prescription drugs, OTC consumer health brands, and established export operations. Closely comparable in therapeutic focus (musculoskeletal, cardiovascular, dermatology) and in the consumer health adjacency.
• Daewoong Pharmaceutical: Korean pharma manufacturer with branded prescription drugs, OTC, and a notable botulinum toxin (Nabota) franchise. Highly comparable to Medica Korea's botox/biologics manufacturing ambitions and core prescription portfolio, though at meaningfully larger scale.
• Hanmi Pharm: A leading Korean specialty pharma with strong generic and innovative drug pipelines and global licensing deals. Comparable to Medica Korea in multi-therapeutic portfolio and CMO orientation, but with materially larger R&D and international footprint.

Direct peers

• Bukwang Pharmaceutical: Korean pharma focused on specialty prescription drugs and new drug development, with selective consumer health adjacencies. Comparable to Medica Korea in specialty pharma positioning and R&D-driven growth ambitions.
• Ildong Pharmaceutical: Korean mid-cap pharma with a similar mix of specialty generics (cardiovascular, GI, neurology), health supplements, and CMO services. Most directly comparable peer in size, therapeutic focus, and Korean-domestic distribution model.
• Chong Kun Dang Pharmaceutical: Korean pharma operating in branded prescription drugs, generics, OTC, and health functional foods. Comparable to Medica Korea in portfolio breadth, KGMP-driven manufacturing, and consumer health adjacencies.
• Korea United Pharm: Mid-sized Korean pharma with KGMP manufacturing, generic and specialty drug portfolio, and CMO/contract services. Closely comparable in size and business mix to Medica Korea.
• Kwang Dong Pharmaceutical: Korean pharma-OTC hybrid with consumer health brands (e.g., Vita 500) alongside prescription drugs. Comparable to Medica Korea's mix of consumer health brands (Bibi-Toktok) and prescription portfolio.
• Samjin Pharmaceutical: Korean mid-cap pharma with multi-therapeutic generics and OTC consumer brands. Comparable to Medica Korea in therapeutic breadth, KGMP manufacturing, and channel mix.

Market position

Strengths5 records

Weaknesses5 records

Competitive moat4 records

Key risks6 records

Key highlights7 records

Customer concentration

• YouTubeyoutube.com/@medicakorea
• Facebookfacebook.com/100067152675829/videos/2022-%EB%A9%94%EB%94%94%EC%B9%B4%EC%BD%94%EB%A6%AC%EC%95%84/242834328035636/?locale=ms_MY
• Instagraminstagram.com/medicakorea_official
• LinkedInlinkedin.com/company/medica-korea-co-ltd

Compliance4 records

Revenue estimate

Valuation estimate

Number of profiles

Profiles1 record

Funding overview

Funding rounds2 records

Investors2 records

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A

Investments

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about Medica Korea